Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus

To investigate the differences in glycemic variability between the long-acting insulins glargine and degludec using continuous glucose monitoring, we conducted an open-label, multicenter, prospective, observational study that enrolled 21 participants with type 1 diabetes mellitus currently receiving...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine Journal 2016, Vol.63(1), pp.53-60
Main Authors: Yamamoto, Chiho, Miyoshi, Hideaki, Fujiwara, Yutaka, Kameda, Reina, Ichiyama, Mei, Nomoto, Hiroshi, Kameda, Hiraku, Nakamura, Akinobu, Atsumi, Tatsuya
Format: Article
Language:English
Subjects:
Adult
Aged
Blood Glucose - drug effects
Blood Glucose - metabolism
Circadian Rhythm
Continuous glucose monitoring
Diabetes Mellitus, Type 1 - blood
Diabetes Mellitus, Type 1 - complications
Diabetes Mellitus, Type 1 - drug therapy
Female
Humans
Hypoglycemia - chemically induced
Insulin degludec
Insulin Glargine - therapeutic use
Insulin, Long-Acting - therapeutic use
Male
Middle Aged
Type1 diabetes mellitus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the differences in glycemic variability between the long-acting insulins glargine and degludec using continuous glucose monitoring, we conducted an open-label, multicenter, prospective, observational study that enrolled 21 participants with type 1 diabetes mellitus currently receiving basal-bolus insulin therapy with glargine. To avoid the potential influence of diet and exercise on glycemic control, all participants were housed and monitored within the hospital for the duration of the study. Once glycemic control was achieved with glargine, glycemic variability was evaluated using continuous glucose monitoring for 3 days. Glargine was then replaced by degludec and glycemic variability again assessed via continuous glucose monitoring. The primary outcome measure of mean amplitude of glycemic excursions was significantly reduced with degludec (p = 0.028), as was area under the curve for daily blood glucose level
ISSN:0918-8959
1348-4540
DOI:10.1507/endocrj.EJ15-0438